Detailansicht

Wissensnetz

Person

Belal Haschimi

Name	Belal Haschimi
Ort	Kabul (Geburtsort) Sonstiges Ausland / Unbekanntes Land
Geschlecht	männlich
Akademischer Grad bzw. Titel	Dr. rer. nat.
Weitere Angaben	Dissertation 2023, Albert-Ludwigs-Universität Freiburg, Fakultät für Chemie und Pharmazie
Quelle	FreiDok plus
Datensatztyp	Person
GND-Nummer	128904676X
Datensatz-ID	128904676X
Beteiligt an alle anzeigen ADB‐HEXINACA - a novel synthetic cannabinoid with a hexyl substituent: phase I metabolism in authentic urine samples, a case report and prevalence on the German market Human metabolism and basic pharmacokinetic evaluation of AP‐238: a recently emerged acylpiperazine opioid Human phase‐I metabolism and prevalence of two synthetic cannabinoids bearing an ethyl ester moiety: 5F‐EDMB‐PICA and EDMB‐PINACA Synthetische Cannabinoide in der forensischen Toxikologie : : Studien zur Pharmakokinetik mittels massenspektrometrischer Analyseverfahren in biologischen Matrices Development and validation of a rapid LC‐MS/MS method for the detection of 182 novel psychoactive substances in whole blood A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: comparing prison and general populations Cumyl‐CBMICA: a new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chain New synthetic cannabinoids carrying a cyclobutyl methyl side chain: human phase‐I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl‐CBMICA and Cumyl‐CBMINACA Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB‐4en‐PICA, MDMB‐4en‐PINACA, ADB‐4en‐PINACA, and MMB‐4CN‐BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays Detection and phase I metabolism of the 7‐azaindole‐derived synthetic cannabinoid 5F‐AB‐P7AICA including a preliminary pharmacokinetic evaluation Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine - potential impact on therapeutic decisions Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE Impact of legislation on NPS markets in Germany – the rise and fall of 5F‐ADB Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Belal Haschimi

ADB‐HEXINACA - a novel synthetic cannabinoid with a hexyl substituent: phase I metabolism in authentic urine samples, a case report and prevalence on the German market

Human metabolism and basic pharmacokinetic evaluation of AP‐238: a recently emerged acylpiperazine opioid

Human phase‐I metabolism and prevalence of two synthetic cannabinoids bearing an ethyl ester moiety: 5F‐EDMB‐PICA and EDMB‐PINACA

Synthetische Cannabinoide in der forensischen Toxikologie : : Studien zur Pharmakokinetik mittels massenspektrometrischer Analyseverfahren in biologischen Matrices

Development and validation of a rapid LC‐MS/MS method for the detection of 182 novel psychoactive substances in whole blood

A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: comparing prison and general populations

Cumyl‐CBMICA: a new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chain

New synthetic cannabinoids carrying a cyclobutyl methyl side chain: human phase‐I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl‐CBMICA and Cumyl‐CBMINACA

Detection and phase I metabolism of the 7‐azaindole‐derived synthetic cannabinoid 5F‐AB‐P7AICA including a preliminary pharmacokinetic evaluation

Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine - potential impact on therapeutic decisions

Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE

Impact of legislation on NPS markets in Germany – the rise and fall of 5F‐ADB

Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE